Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
19 studies found for:    Multiple System Atrophy with Orthostatic Hypotension
Show Display Options
Download search resultsDownload the search results for:
Multiple System Atrophy with Orthostatic Hypotension (19 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy
Conditions: Parkinson's Disease;   Multiple System Atrophy;   Orthostatic Hypotension
Interventions: Drug: Fludrocortisone;   Drug: Domperidone;   Behavioral: Conservative Measures for Orthostatic Hypotension
2 Recruiting Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA
Condition: Multiple System Atrophy
Interventions: Drug: L-Threo DOPS;   Drug: placebo
3 Unknown  Fipamezole in Neurogenic Orthostatic Hypotension
Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH);   Parkinson's Disease;   Multiple System Atrophy
Interventions: Drug: Placebo;   Drug: Fipamezole
4 Active, not recruiting Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension
Conditions: Orthostatic Hypotension;   Pure Autonomic Failure;   Multiple System Atrophy;   Parkinson's Disease
Intervention:
5 Completed
Has Results
Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
Conditions: Neurogenic Orthostatic Hypotension;   Non-Diabetic Autonomic Neuropathy;   Multiple System Atrophy;   Dopamine Beta Hydroxylase Deficiency
Interventions: Drug: Droxidopa;   Drug: Placebo
6 Completed
Has Results
A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa
Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH);   Non-diabetic Neuropathy;   Primary Autonomic Failure;   Dopamine Beta Hydroxylase Deficiency
Interventions: Drug: Placebo;   Drug: Droxidopa
7 Completed
Has Results
Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH);   Non-diabetic Neuropathy;   Primary Autonomic Failure;   Dopamine Beta Hydroxylase Deficiency
Interventions: Drug: Placebo;   Drug: Droxidopa
8 Recruiting A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy
Conditions: Symptomatic Neurogenic Orthostatic Hypotension;   Parkinson's Disease;   Multiple Systems Atrophy;   Pure Autonomic Failure;   Dopamine Beta Hydroxylase Deficiency
Interventions: Drug: Droxidopa;   Drug: Placebo
9 Recruiting Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) Study
Condition: Multiple System Atrophy
Interventions: Radiation: PET (Positron Emission Tomography) Study;   Other: Brain MRI  (magnetic resonance imaging);   Drug: Fluoxétine / Placebo
10 Completed Droxidopa in Treating Patients With Neurogenic Hypotension
Conditions: Shy-Drager Syndrome;   Orthostatic Hypotension
Intervention: Drug: droxidopa
11 Recruiting The Phenotype and Natural History of Primary Autonomic Disorders
Condition: Neurogenic Orthostatic Hypotension
Intervention:
12 Completed Fluoxetine in Multiple System Atrophy Patients
Condition: Multiple System Atrophy
Intervention: Drug: FLUOXETINE
13 Completed A Study for Patients With Neurogenic Orthostatic Hypotension
Condition: Hypotension, Orthostatic
Intervention: Drug: Midodrine Hydrochloride
14 Terminated A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension
Condition: Hypotension, Orthostatic
Intervention: Drug: midodrine hydrochloride (ProAmatine®)
15 Recruiting Post-prandial Hypotension and Sleepiness in Parkinson's Disease and Other Synucleinopathies
Conditions: Parkinsonian Patients;   Post-prandial Sleepiness;   Orthostatic Hypotension
Interventions: Other: V1: HGPO + meal and V2: placebo + meal;   Other: V1: placebo 75mg + meal and V2: HGPO 75mg + meal
16 Active, not recruiting Nebivolol in the Supine Hypertension of Autonomic Failure
Conditions: Hypertension;   Pure Autonomic Failure;   Multiple System Atrophy
Interventions: Drug: Placebo;   Drug: Nebivolol 5 mg;   Drug: metoprolol tartrate 50 mg;   Drug: Sildenafil25 mg
17 Recruiting Treatment of Supine Hypertension in Autonomic Failure
Condition: Hypertension
Interventions: Drug: Clonidine;   Drug: Nitroglycerin transdermal;   Drug: Dipyridamole/ Aspirin (Aggrenox);   Drug: Desmopressin (DDAVP);   Drug: Sildenafil;   Drug: Nifedipine;   Drug: Hydralazine;   Drug: Hydrochlorothiazide;   Drug: Placebo;   Drug: Bosentan;   Drug: Diltiazem;   Drug: Eplerenone;   Drug: guanfacine;   Dietary Supplement: L-arginine;   Drug: captopril;   Drug: carbidopa;   Drug: losartan;   Drug: metoprolol tartrate;   Drug: nebivolol hydrochloride;   Drug: prazosin hydrochloride;   Drug: tamsulosin hydrochloride;   Other: Head-up tilt.;   Drug: aliskiren;   Other: Local heat stress
18 Recruiting Magnetic Resonance Spectroscopy in Autonomic Failure
Conditions: Pure Autonomic Failure;   Multiple System Atrophy
Intervention: Procedure: Magnetic Resonance Spectroscopy Imaging
19 Completed Autonomic Failure Patients for RNA Blood Sampling
Conditions: Pure Autonomic Failure;   Multiple System Atrophy;   Parkinson's Plus Syndromes
Intervention:

Indicates status has not been verified in more than two years